-
1.发明申请公开(公告)号：US20140219979A1
公开(公告)日：2014-08-07
申请号：US14221887
申请日：2014-03-21
Inventor： Irun R. Cohen , Alexandra Zanin-Zhorov , Guy Tal , Francisco Quintana , Meirav Pisner , Ofer Lider
CPC classification number: A61K38/1709 , A61K35/17 , A61K39/0008 , A61K2035/124 , A61K2039/5158 , A61K2039/53 , C12N5/0636 , C12N2501/07
Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.
Abstract translation: 本发明提供了人类热休克蛋白60（HSP60）的肽p277-位置437-460在调节免疫应答和炎性疾病方面的新用途。 本发明进一步提供HSP60和p277在治疗或预防肝病中的新用途。 本发明公开了治疗，预防或改善T细胞介导的炎症和自身免疫性疾病（包括肝脏疾病）的症状的方法，其包括向有需要的受试者施用包含有效量的选自以下的分子的组合物： HSP60，p277，其片段，类似物，同源物及其衍生物，以及编码其的核酸。 还公开了用于治疗或预防T细胞介导的病症的T细胞疫苗接种方法。
-
公开(公告)号：JP6215203B2
公开(公告)日：2017-10-18
申请号：JP2014526601
申请日：2012-08-23
Inventor： シェルツ,アビグドル , サロモン,ヨラム , マルコビチ,アリー , ブランディス,アレクサンダー , ワーグナー,ダニエル
IPC: A61P27/02 , A61P27/06 , A61P27/10 , A61K31/409 , A61P43/00 , A61K9/08 , A61K47/36 , C07F15/00 , A61K41/00
CPC classification number: A61K41/0071 , A61K31/407 , A61K31/519 , A61K31/555 , A61K47/186 , A61K47/36 , A61K9/0048 , A61N5/062 , A61N2005/0659
-
公开(公告)号：JP2014122245A
公开(公告)日：2014-07-03
申请号：JP2014071034
申请日：2014-03-31
Applicant: Cedars-Sinai Medical Center , セダーズ−シナイ メディカル センター , Yeda Research And Development Co Ltd , イーダ リサーチ アンド ディベロップメント カンパニー リミテッド
Inventor： YOSEF KORONYO , MAYA KORONYO , BLACK KEITH L , MICHAL SCHWARTZ , DANIEL FARKAS
CPC classification number: A61K49/0021 , A61K49/006
Abstract: PROBLEM TO BE SOLVED: To provide an optical method for detecting Alzheimer disease.SOLUTION: The main subject of the present invention relates to a non-invasive optical imaging method for monitoring an initial pathological event (e.g., generation of amyloid plaque, the amount and position thereof) specific to Alzheimer disease (AD). The capability of monitoring such an event provides a basis for AD diagnosis, prognosis prediction and potential therapy evaluation, above all. Further, the main subject of the present invention is to introduce a new method for treating AD and a retinal disease related with AD. Aβ plaque detection is extremely limited particularly in terms of high resolution. Therefore, the present invention is based on a study focusing on an eye, as alternative means of a tissue from the brain, which can be directly, repeatedly and non-invasively imaged.
Abstract translation: 要解决的问题：提供用于检测阿尔茨海默病的光学方法。解决方案：本发明的主要课题涉及用于监测初始病理事件的非侵入性光学成像方法（例如，淀粉样斑块的产生，量和 位置），其特异于阿尔茨海默病（AD）。 首先，监测这种事件的能力为AD诊断，预后预测和潜在治疗评估提供了依据。 此外，本发明的主要目的是引入一种治疗AD和与AD相关的视网膜疾病的新方法。 A＆BGR; 特别是在高分辨率方面，斑块检测非常有限。 因此，本发明基于着眼于眼睛的研究，作为可以直接，重复和非侵入性成像的来自脑的组织的替代手段。
-
公开(公告)号：JP6276252B2
公开(公告)日：2018-02-07
申请号：JP2015502555
申请日：2013-03-21
Applicant: イェダ リサーチ アンド ディベロップメント カンパニー リミテッド , YEDA RESEARCH AND DEVELOPMENT CO. LTD , ニューロクエスト リミテッド
Inventor： アイゼンバッハ−シュワルツ,ミハエル , ヨールズ,エステル
IPC: G01N33/53
CPC classification number: G01N33/56972 , G01N33/5047 , G01N33/505 , G01N2800/2821 , G01N2800/50 , G01N2800/52
-
公开(公告)号：JP2020533408A
公开(公告)日：2020-11-19
申请号：JP2020535321
申请日：2018-09-07
Applicant: 学校法人慶應義塾 , バイオミクス リミテッド , BIOMX LTD. , イェダ リサーチ アンド ディベロップメント カンパニー リミテッド アット ザ ワイツマン インスティチュート オブ サイエンス , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE
Inventor： 本田 賢也 , 新 幸二 , 成島 聖子 , エラン エリナブ , ロテム ソレック , エフラット カブラ , ハヴァ ベン ダビッド , エヤル ウェインストック , サラ ポロック , ユリア ムティウヒン , ナオミ ザック
Abstract: 本明細書に開示されるのは、バクテリオファージ組成物およびその処置的使用である。本開示はまた、クレブシエラ細菌株(例えば、炎症性腸疾患に関連し、それによって疾患を制御し得る株)を溶解し得るバクテリオファージに関する。
-
Patent Agency Ranking
公开(公告)号：US12286439B2
公开(公告)日：2025-04-29
申请号：US17337570
申请日：2021-06-03
Applicant: Yeda Research and Development Co. Ltd. , Universitat de Barcelona , Institució Catalana de Recerca I Estudis Avançats
Inventor： Rony Seger , Karen Flores , Xavier Barril Alonso , Carlos Galdeano Cantador
IPC: C07D498/04 , A61K45/06 , A61P35/00
Abstract: Described herein are compounds having Formula I or Formula II: wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R′1 are aryl or heteroaryl as defined herein; and R2 and R′2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.
-
7.发明申请公开(公告)号：US20250127783A1
公开(公告)日：2025-04-24
申请号：US18694557
申请日：2022-09-23
Applicant: DANA-FARBER CANCER INSTITUTE, INC. , BETH ISRAEL DEACONESS MEDICAL CENTER, INC. , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Shizhong KE , Gerburg WULF , Xiao Zhen ZHOU , Nir LONDON , Wenyi WEI , Kun Ping LU , Nathanael S. GRAY , Behnam NABET
IPC: A61K31/519 , A61K31/203 , A61K31/381 , A61K31/506 , A61K33/36 , A61P35/00 , C07K16/28
Abstract: Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
-
公开(公告)号：US20250127492A1
公开(公告)日：2025-04-24
申请号：US19001657
申请日：2024-12-26
Applicant: New York University , Yeda Research And Development Co. Ltd
Inventor： Itay KEZURER , Achiau LUDOMIRSKY , Yaron LIPMAN
Abstract: A system and method for detecting at least one cardiac anomaly includes a specifically configured computer hardware arrangement configured to receive ultrasound imaging information related to a heart of a patient and to use at least one neural network trained on multiple recognition and analysis procedures to detect at least one anomaly and/or to classify a severity of at least one anomaly.
-
公开(公告)号：US20250122311A1
公开(公告)日：2025-04-17
申请号：US18681143
申请日：2022-08-05
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Sarel FLEISHMAN , Ariel TENNENHOUSE
Abstract: Provided herein is a method for obtaining a humanized antibody based on a non-human antibody having an affinity to an antigen of interest, that starts from an experimental or model structure, grafts the non-human CDRs on a library of human frameworks and uses restrained/constrained atomistic simulations to relax and rank the designs by energy.
-
公开(公告)号：US20250092158A1
公开(公告)日：2025-03-20
申请号：US18832710
申请日：2022-08-04
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Deborah FASS , Sarel FLEISHMAN , Lev KHMELNITSKY , Ariel TENNENHOUSE
IPC: C07K16/40 , A61K39/00 , A61K47/68 , G01N33/573
Abstract: The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.
-
-
-
-
-
-
-
-
-
Search Results
2284
records
(took 0.048 seconds)
